SCHEMBL30135007

SCHEMBL30135007

Nc1nc(-c2ccnc3c2ccn3S(=O)(=O)c2ccccc2)cs1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.50
ATP4A P20648 1/20 0.44
ATP4B P51164 1/20 0.44
HTR6 P50406 8/20 0.42
DRD2 P14416 2/20 0.42
HTR2A P28223 1/20 0.42
PKM P14618 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MET P08581 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 2/20 0.38
HTT P42858 2/20 0.38
KMT2A Q03164 2/20 0.38
HSD17B10 Q99714 1/20 0.37
TSHR P16473 1/20 0.37
MPL P40238 1/20 0.37
PIK3C3 Q8NEB9 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135084 0.80 ALDH1A1 (0.45) ATP4AATP4BHTR6DRD2ALDH1A1
SCHEMBL30135143 0.79 CYP2C19 (0.51) CYP2C19HTR6DRD2HTR2APKM
SCHEMBL16040182 0.78 CYP2C19 (0.51) CYP2C19HTR6DRD2HTR2APKM
SCHEMBL28585014 0.78 CYP2C19 (0.58) CYP2C19HTR6DRD2HTR2APKM
SCHEMBL4593041 0.77 CYP2C19 (0.47) CYP2C19HTR6DRD2HTR2APKM
SCHEMBL19104421 0.77 CYP2C19 (0.45) CYP2C19HTR6DRD2HTR2APKM
SCHEMBL31668630 0.76 HTR6 (0.50) CYP2C19HTR6DRD2HTR2AMET
SCHEMBL18340689 0.75 CYP2C19 (0.47) CYP2C19HTR6DRD2HTR2APKM
SCHEMBL16052009 0.74 CYP2C19 (0.52) CYP2C19HTR6DRD2HTR2APKM
SCHEMBL25322767 0.74 CYP2C19 (0.46) CYP2C19HTR6DRD2HTR2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243196-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION 2025-07-31 US disclosed
WO-2022216717-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION (US) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243196-A1 CITRON KINASE INHIBITORS CHEK2, CILK1, DCK CYP2C19 4454/4885ATP4A 4264/4885ATP4B 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.